<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_emtricitabine.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:37 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Emtricitabine</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">03-24-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>
<B>Available formulation in Zambia: Capsule: </B>200 mg; <B>Oral liquid: </B>10 mg/ml. <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>&nbsp;300&nbsp;mg/FTC&nbsp;200&nbsp;mg combination tab <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>&nbsp;600&nbsp;mg/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>&nbsp;300&nbsp;mg/FTC&nbsp;200&nbsp;mg combination tab </li>
<li>FTC/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> plus <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> or NVP is now preferred firstline regimen due to long-term potency and favorable mutation pathway. </li>
<li>Refrigerate FTC solution. Solution can be kept out at room temperature for 3 months only. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in combination with other antiretroviral agents.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">NON-FDA APPROVED USES</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">hepatitis B</A> in HIV-<A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A> co-infected pts. or in <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A> mono-infected patients.</li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Emtriva</I>
          </TD><TD valign="top">Emtricitabine (FTC)</TD><TD valign="top">Gilead</TD><TD>Oral</TD><TD>capsule</TD><TD>200 mg</TD><TD>$10.11 per cap</TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Truvada</I>
          </TD><TD valign="top">Emtricitabine (FTC)+ <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">Tenofovir DF (TDF)</A></TD><TD valign="top">Gilead</TD><TD>Oral</TD><TD>tablet</TD><TD>FTC200 mg/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> 300 mg</TD><TD>$27.62 per tab</TD>
</TR>
        
<TR>
<TD valign="top">Atripla </TD><TD valign="top">Emtricitabine (FTC)+ <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">Tenofovir</A> DF (<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>) + <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">Efavirenz</A> (<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>) </TD><TD valign="top">Bristol-Myers Squibb / Gilead </TD><TD>Oral </TD><TD>tablet </TD><TD>FTC200mg/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>300 mg/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg </TD><TD>$47.95 per tab </TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>Pill burden: 1 cap or tab qd<br>
<br>
<ul>
<li>FTC 200 mg - 1 tab qd with or without food. </li>
<li>Can be administered as a co-formulated product with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">tenofovir DF </A>(<I>Truvada</I>) 1 tab PO qd with or without food and <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> (<I>Atripla</I>) 1 tab qd. Evening dosing on an empty stomach recommended with initial Atripla therapy to decrease <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-associated side effects.</li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>200 mg q24hrs. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>30-49 mL/min: FTC 200 mg q48hrs or <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/FTC co-formulation (Truvada) 1 tab q48h ;15-29 mL/min: FTC 200 mg q72hrs. <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/FTC co-formulation (Atripla) not recommended with GFR &lt;50 ml/min). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>&lt;15 mL/min: 200 mg q96hrs. <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/FTC (Truvada) and <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/FTC co-formulation (Atripla) not recommended with GFR &lt;50 ml/min). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>200 mg q96hrs post-HD (30% of dose removed with 3-hr HD). <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/FTC co-formulation (Atripla) not recommended with GFR &lt;50 ml/min). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>No data. Consider dose reduction. <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/FTC (Truvada) and <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/FTC co-formulation (Atripla) not recommended with GFR &lt;50 ml/min). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data. Consider dose reduction. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">GENERAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Generally well tolerated. For <I>Atripla</I>, see <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> for <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-associated side effects and <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> for <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>-associated side effects</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Mild asymptomatic skin hyperpigmentation on the palm and/or soles, with increased frequency in dark-skinned individuals. </li>
<li>Asymptomatic and transient CPK elevation. </li>
<li>Headache, <A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">diarrhea</A>, nausea, asthenia, and rash that required discontinuation in approx. 1% of pts. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lactic_acidosis9dee.html?contentInstanceId=432782">Lactic acidosis</A> (categorized as NRTI class adverse effect, but not expected to occur frequently with FTC).</li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>Not a substrate, inhibitor, or inducer of any CYP450 isoforms. No clinically significant drug interactions.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>
          </B></TD><TD valign="top">No significant drug interaction.</TD><TD valign="top">Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">Tenofovir</A> Cmin was increased by 20%; AUC was unchanged.</TD><TD valign="top">Interaction not significant. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Food</B></TD><TD valign="top">FTC AUC was not affected by food.</TD><TD valign="top">Administer FTC with or without food</TD>
</TR>
</TABLE>
<a name="SPECTRUM"></a>
<h2 class="grayLineHeaderBar">SPECTRUM</h2>
<a name="N1093A"></a>
<TABLE CELLPADDING="0" CELLSPACING="0"  BORDER="0"></TABLE>
<ul>
<li>HIV and <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A>
</li>
</ul>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>184V: High-level resistance.</li>
<li>T69ins: High-level resistance. </li>
<li>Q151M complex: Unknown data, but low-level resistance likely. </li>
<li>TAMs (41L, 210W, 215Y/F, 219Q/E, 44D, 67N, 70R, 118I): high level resistance with multiple TAMs.</li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10963"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Intracellular phosphorylation to active triphosphate, which competitively inhibits HIV DNA polymerase. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                FTC is well absorbed with an absolute bioavailability of 93%. </li>
<li>Metabolism and Excretion: 
                Only 13% of administered dose is metabolized to sulfadoxide and glucuronide metabolites. Metabolites and unchanged drug are excreted primarily via glomerular filtration and tubular secretion.</li>
<li>Protein Binding: 
                &lt;4%</li>
<li>Cmax, Cmin, and AUC: 
                Mean Cmax=1.8 g/mL; Cmin=0.09 g/mL; AUC 10 mcg hr/mL after 200 mg qd at steady-state. </li>
<li>T1/2: 
                10 hrs </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>No data: Usual dose likely.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category B. No human data. In animal studies, FTC at 120-fold higher than human exposure did not result in fetal malformation.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>No data. Breast feeding is not recommended for HIV-infected pts in the U.S.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: Activity against <A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b4390.html?contentInstanceId=432701">HBV</A>; well tolerated; qd dosing; co-formulation with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>; similar to <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> with respect to activity, tolerability, and resistance profile</li>
<li>Cons: Hyperpigmentation in some pts; less clinical data than for <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>. </li>
</ul>
<a name="N109B4"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Gallant JE, DeJesus E, Arribas JR, et al.;
		Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.;        
		N Engl J Med;
		2006; Vol. 
		354; pp. 
		251-60;
		<br>ISSN:
	        	1533-4406;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16421366&amp;dopt=abstract" target="_new">16421366</a>
<br>
<b>Comments:</b>Ongoing 144-wk multicenter, open-label trial comparing <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> + FTC vs. co-formulated AZT/3TC, both administered in combination with <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>, in 509 treatment-nave pts. Mean baseline VL 5.0 log10 . At 48 wks, 84% of the 487 evaluable pts in the <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> + FTC arm had a Vl &lt;400 compared to 73% in the AZT/3TC arm (p=0.002) by the FDA-mandated time to loss of viral response analysis. Suppression to &lt;50 was achieved in 80 and 70% of pts, respectively (p=0.02). Higher ITT success rate in the <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/FTC arm was due to a higher rate of discontinuation caused by AEs in the AZT/3TC arm (9% vs 4%; p=0.016), with 6% discontinuing due to <A class="headLines" target="_new" href="../../diagnosis/organ_system/anemiac7e4.html?contentInstanceId=432360">anemia</A>. <br>
<br>
</li>
<li>Saag MS, Cahn P, Raffi F, et al.;
		Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.;        
		JAMA;
		2004; Vol. 
		292; pp. 
		180-9;
		<br>ISSN:
	        	1538-3598;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15249567&amp;dopt=abstract" target="_new">15249567</a>
<br>
<b>Comments:</b>FTC 301 study: 48 wk double-blind study that compared qd FTC or bid <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>, both given in combination with ddI and <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>. 571-naive pts with a mean baseline CD4 of 318 (range 5-1317) and med. baseline VL of 4.9 (range 2.6-7.0) randomized to receive FTC qd or <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> bid, both in combination with ddI and <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> qd. The probability of persistent virological response &lt;50 through wk 60 was 76% for the FTC group vs 54% for the d4T group (p &lt;.001). <br>
<br>
</li>
<li>Wakeford C, Shen G, Hulett L, et al. ;
		Long-Term Efficacy and Safety of Emtricitabine in HIV-Positive Adults Switching From a Lamivudine Containing HAART Regimen ;        
		10th Conference on Retroviruses and Opportunistic Infections, Boston, Mass. February 10-14, 2003; Abstract 550. ;
		2003 ; Vol. 
		<br>
<b>Comments:</b>FTC 303 study: 440 pts on a 3TC-containing regimen with VL &lt;400 randomized to switch to FTC or continue <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> with maintenance of background regimen. 67% and 72% of pts randomized to FTC and 3TC achieved and maintained VL &lt;50 through wk 48 (p=NS), respectively. Mean increase from baseline CD4 was 29 for FTC and 61 for <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>. In pts who elected to continue FTC after wk 48, 47% maintained an undetectable VL at wk 120. <br>
<br>
</li>
<li>Molina JM, et al. ;
		Once-daily combination of FTC, ddI, and EFV vs. continued PI-based HAART in HIV-infected adults with undetectable plasma HIV-RNA: 48-week results of a prospective randomized multicenter trial ;        
		10th Conference on Retroviruses and Opportunistic Infections, Boston, Mass. February 10-14, 2003; Abstract 551. ;
		2003 ; Vol. 
		<br>
<b>Comments:</b>ANRS 099 (Alize Study): open-label, non-inferiority study involving 355 pts receiving a PI-based regimen with VL &lt;400. Pts randomized to continue PI-based regimen or switch to qd regimen of FTC, ddI, and <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>. Non-inferiority defined as a difference in proportion of success between the 2 groups of &lt;15%. In an ITT analysis, 87% and 95% of pts randomized to PI-based regimen vs. qd regimen maintained VL &lt;50, respectively (p&lt;0.05). <br>
<br>
</li>
<li>Molina JM, No E, Raffi F, et al. ;
		Once-daily combination therapy with emtricitabine (FTC), didanosine (ddI), and efavirenz (EFV) in treatment naive HIV-infected adults: 3-ear follow-up of the MONTANA (ANRS) trial ;        
		2nd IAS Conference on HIV Pathogenesis and Treatment, Paris France. July 13-16, 2003; Abstract 594. ;
		2003 ; Vol. 
		<br>
<b>Comments:</b>At 3 yrs, 75% of pts (30/40) maintained a VL &lt;400 (ITT, 95% CI: 59%-87%). <br>
<br>
</li>
</ol>
<a name="REFERENCED WITHIN THIS GUIDE"></a>
<h2 class="grayLineHeaderBar">REFERENCED WITHIN THIS GUIDE</h2>
<ul>
<li>
<A class="headLines" target="_new" href="abacavir5909.html?contentInstanceId=432943&amp;siteId=429188">Abacavir</A>
</li>
<li>
<A class="headLines" target="_new" href="efavirenz5909.html?contentInstanceId=432943&amp;siteId=429188">Efavirenz</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/hepatitis_b5909.html?contentInstanceId=432943&amp;siteId=429188">Hepatitis B</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/initial_regimen_for_arv_therapy5909.html?contentInstanceId=432943&amp;siteId=429188">Initial Regimen for ARV Therapy</A>
</li>
<li>
<A class="headLines" target="_new" href="lamivudine5909.html?contentInstanceId=432943&amp;siteId=429188">Lamivudine</A>
</li>
<li>
<A class="headLines" target="_new" href="lopinavir_ritonavir5909.html?contentInstanceId=432943&amp;siteId=429188">Lopinavir/Ritonavir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/post-exposure_prophylaxis5909.html?contentInstanceId=432943&amp;siteId=429188">Post-exposure prophylaxis</A>
</li>
<li>
<A class="headLines" target="_new" href="tenofovir5909.html?contentInstanceId=432943&amp;siteId=429188">Tenofovir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/toxicity___side_effects__switching_therapy__zambia_spec5909.html?contentInstanceId=432943&amp;siteId=429188">Toxicity &amp; side effects: switching therapy (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/tuberculosis__active__zambia_specific_5909.html?contentInstanceId=432943&amp;siteId=429188">Tuberculosis, Active (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="zidovudine5909.html?contentInstanceId=432943&amp;siteId=429188">Zidovudine</A>
</li>
</ul>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_emtricitabine.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:37 GMT -->
</html>
